Tim Hunt

A worrisome new ideological shift at the Food and Drug Administration threatens to undermine President Trump's worthy goals -- from within. REUTERS Months into his second term, President Donald Trump’s top health officials were clear. They promised to focus on “cures” and “meaningful treatments.” They wanted revolutionary medicine to be developed in the United States. They didn’t want the treatments of tomorrow to come from China.

Recent headlines have spotlighted challenges in the cell and gene therapy sector, from trial suspensions and product holds to delayed approvals and increased scrutiny of clinical data. While these developments have understandably raised important questions about the use of cell and gene therapies, the field is making significant underappreciated progress.

Tim joined ARM as CEO in 2022 with more than 20 years of experience in the biotechnology industry. A company-builder with a focus on corporate culture, he has helped early-stage organizations create internal cohesion and advance strategic initiatives. As chief executive, Tim divides his time between managing ARM and its global staff of nearly 30 employees and serving as an external advocate on behalf of ARM’s membership and the broader cell and gene therapy sector.